Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of gp145 C.6980 HIV Vaccine in Healthy Adults
NCT03382418Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2017
- Primary completion
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gp145 C.6980 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness at 7 days, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration at 7 days and 4 more. Started Dec 2017; status: completed.
02
Drugs
gp145 C.6980
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03382418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382418.